Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Cash from Operations (2010 - 2026)

Lite Strategy (LITS) posted Cash from Operations of -$1.5 million for Q1 2026, up 21.2% on a QoQ basis from -$1.9 million in Q4 2025, and up 53.47% year-over-year from -$990394.9 in Q1 2025.

Analysis

Lite Strategy (LITS) Cash from Operations (2010 - 2026) Analysis & Trends

Lite Strategy has reported Cash from Operations for 17 years, with the latest figure at -$1.5 million in Q1 2026.

  • On a quarterly basis, Cash from Operations rose 53.47% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was -$10.4 million, a 71.36% increase from a year earlier, with the FY2025 full-year figure at -$20.8 million, up 58.7% from the prior year.
  • Cash from Operations was -$1.5 million for Q1 2026 at Lite Strategy, up from -$1.9 million in the prior quarter.
  • The five-year high for Cash from Operations was -$1.5 million in Q1 2026, with the low at -$18.5 million in Q3 2023.
  • Average Cash from Operations over 5 years is -$9.7 million, with a median of -$11.3 million recorded in 2023.
  • The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 91.45% in 2022, then jumped 86.33% in 2025.
  • Over 5 years, Cash from Operations stood at -$14.3 million in 2022, then advanced by 22.53% to -$11.1 million in 2023, then jumped by 66.84% to -$3.7 million in 2024, then jumped by 47.38% to -$1.9 million in 2025, then grew by 21.2% to -$1.5 million in 2026.
  • The last three Cash from Operations figures came in at -$1.5 million (Q1 2026), -$1.9 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 4.00 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 3.57 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.13 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 813.00 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -526.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 326.72 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 448.90 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -270.50 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn - -1.52 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.52 Mn
Dec 31, 2025 -1.93 Mn
Sep 30, 2025 -4.51 Mn
Jun 30, 2025 -2.46 Mn
Mar 31, 2025 -3.27 Mn
Dec 31, 2024 -3.67 Mn
Sep 30, 2024 -11.45 Mn
Jun 30, 2024 -18.00 Mn
Mar 31, 2024 -2.93 Mn
Dec 31, 2023 -11.06 Mn
Sep 30, 2023 -18.49 Mn
Jun 30, 2023 -11.30 Mn
Mar 31, 2023 -12.13 Mn
Dec 31, 2022 -14.27 Mn
Sep 30, 2022 -14.78 Mn
Jun 30, 2022 -15.50 Mn
Mar 31, 2022 -16.96 Mn
Dec 31, 2021 -8.57 Mn
Sep 30, 2021 -7.72 Mn
Jun 30, 2021 -11.26 Mn